Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
Eli Lilly on Thursday reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound spike. Shares of Eli Lilly jumped more than 7% on Thursday. The drugmaker now expects revenue for the year to…